

DOI: 10.5281/zenodo.4028393

UDC: 616.98:579.852.13+616-083.98:614.2



Clostridium difficile infection in the intensive care unit

¹Gheorghe Placinta, ²Valentina Vorobjit, ¹Victor Pantea, ¹Lilia Cojuhari,
¹Valentin Ceboatarescu, ³Lidia Placinta, ³Dan Croitoru

¹Department of Infectious Diseases, ²Department of Microbiology and Immunology

³Department of Infectious Diseases, Tropical and Medical Parasitology

Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, the Republic of Moldova

Authors' ORCID iDs, academic degrees and contribution are available at the end of the article

*Corresponding author: gheorghe.placinta@usmf.md

Manuscript received July 16, 2020; revised manuscript September 07, 2020; published online October 05, 2020

Abstract

Background: *Clostridium difficile* (CD) infection is widespread throughout the world, showing an increased incidence over the recent years and may cause severe forms of disease. This infection most commonly affects patients whom were administered antibiotics. An increased resistance to commonly used antibiotics is associated with *Clostridium difficile* infection (CDI). CD has a generally recognized infectious potential on a clinical ground. CDI is unpleasant and may sometimes cause serious bowel disorders that are usually treated with another course of antibiotics. The evolution of CD infection depends on the individual characteristics of the patient along with risk factors, associated diseases as well as the particularities of the recommended treatment. However, even under the conditions of a correct and complete treatment the risk of the disease relapse is estimated to occur depending on risk factors. Many clinical instruments that are designated for the purposes to treat non-infectious diseases can be useful in estimating the severity of an infection. This review is important for understanding the abusive and irrational prescription of various groups of antibiotics, often unjustified, including the ones used in the treatment of an infection with SARS-CoV-2.

Conclusions: These infections mostly occur in people aged 65 and older that receive medical care, including antibiotics administration, people with a long-term hospital stay, people with a weakened immune system or with a previous CD infection. The following measures, in order to reduce the risk of CDI in patients, should be considered: hand hygiene, avoidance of unnecessary administration of antibiotics – the antibiotic treatment is recommended only if it is prescribed by an experienced specialist, avoidance of unnecessary administration of drugs that reduce gastric acidity, because it favors the invasion of the gastrointestinal tract with CD.

Key words: *clostridium difficile*, risk factors, treatment options.

Cite this article

Placinta G, Vorobjit V, Pantea V, Cojuhari L, Ceboatarescu V, Placinta L, Croitoru D. *Clostridium difficile* infection in the intensive care unit. *Mold Med J*. 2020;63(4):63-67. doi: 10.5281/zenodo.4028393.

Introduction

Clostridium difficile (CD) is a gram positive, anaerobic and spore-forming bacillus [1]. CD causes a toxin-mediated colitis by expressing the toxin A and toxin B [2, 3] that are encoded by the *tcdA* and *tcdB* genes. These toxins lead to intercellular gap cytoskeleton destruction that results in cell death via apoptosis and necrosis [3] and in turn to pseudo-membranous colitis [4, 5]. Sometimes a binary *Clostridium difficile* toxin (CDT) is expressed in hypervirulent CD species [2, 5]. The A+B+CDT-genotype was identified in 87.13% of cases in a brief study made in Shanghai (China) [6]. This microorganism may be transmitted within a community, causing a community-acquired *Clostridium difficile* infection (CDI), or within the hospitals, leading to a health-care-associated CDI [7-10]. A study conducted in Spain revealed that 16% of the CDI were acquired before Intensive Care Unit (ICU) admission or before hospital admission and are commonly more severe [11]. The incidence of CDI is decreasing over the last 10 years in Spain [11]. A study showed that less than 1% of patients developed healthcare-

associated CDI, but a high risk of recurrence and complications was associated with a long ICU stay [12].

On the other hand, the incidence and severity of *Clostridium difficile*-associated diarrhea (CDAD) have increased in the United States of America (USA) [13]. Up to 50% of newborns have a CDI in the first 10 days of life, and up to 70% in the first 30 days of life [9]. Other sources inform that up to 35% of infants had CDI within the ICU [10]. It is reported that CD causes 12-12.1% [14, 15] or 21-22.4%, according to another source, [16] of all healthcare-associated infections. The incidence of CDAD in hospitalized patients ranges between 3-29% [17, 18]. The prevalence for CDI in India was 5.6-15.4% [19], in Kuwait – 6.42% [20].

There is a seasonal incidence for CDI, being higher in March-June then in October-December in the Northern Hemisphere and Asia [21]. Approximately 1/3 of the patients who develop antibiotic-associated diarrhea will become infected with CD [22]. Almost one-third of hospital-associated CD infections referred to asymptomatic adult

carriers [9] in which the mortality incidence ranges between 3.4-15.1% [23].

Bacterial antibiotic resistance is a growing global concern [24], this fact being also observed for the CD occurrence [25]. ICU patients have a higher risk to develop CDI [26]. Antibiotic-associated diarrhea (AAD) is present in 25-30% of the patients who take antibiotics, which is defined as 3 or more loose stools over 24 h [27].

The purpose of this study is to identify the most important risk factors and treatment options that are currently available for a CDI. The PubMed database was used in order to identify the relevant scientific articles. The following keywords were used: “*Clostridium difficile* in the intensive care unit”, March 7, 2020. The study was carried out by analyzing the 100 scientific articles that were identified using the PubMed search engine, after excluding the scientific articles that were published before 2015 and were irrelevant (42 articles), finally 58 scientific articles remained. 13 sources were identified in a non-systematic manner after using the keywords “*Clostridium difficile* diagnostic”. The study was performed on the prevalence, incidence and regional specificity of CD management including the risk factors, treatment options and the prevention methods within the ICU.

Results and discussion

Risk factors

The present study identified the following risk factors that were mentioned in one or more sources that were associated with the ICU:

1. Proton pump inhibitors [1, 3, 27-33]. One of the literature sources proves it wrong [14].
2. The use of some antibiotics is proven to be the leading cause of CDI [1, 14, 33-37] as well as administration of antimicrobial drugs [38] or long-term and multiple use of antimicrobials [13, 39, 40]. Clindamycin, cephalosporins, penicillins and fluoroquinolones are the antibiotics that commonly increase the risk of a CDI [3].
3. Advanced age (>65 years) [1, 3, 27, 39] and a long hospital stay [1, 3, 27, 39, 41].
4. Healthy adults, peripartum women and young children that are admitted to hospitals are the most incident carriers of CD [42].
5. Chemotherapy [3, 27] and H₂ receptor blockers [3].
6. Several comorbidities or comorbidity-related conditions, such as an increased serum creatinine level (an indicator of renal dysfunction) at the time of ICU admission [13, 14], admission to a neurological ICU [14], immunocompromising conditions, inflammatory bowel disease (IBD) [13], diabetes mellitus [18, 27], malignant neoplasms [13, 38], cirrhosis, hypalbuminemia [36], fever, metabolic disorders [40].
7. Surgical intervention is a known risk factor for CDI, at the same time a known treatment option for patients

with severe CDI [44], preoperative acute renal failure and postoperative acute hyperglycemia are regarded as isolated risk factors [45].

8. Chronic obstructive pulmonary disease (COPD) was positively associated with CDI in trauma/surgery patients compared with medical patients [41].
9. Positive toxin test, because it may not always indicate a CDI [43].

In addition, were identified unexpected neutral factors:

1. Trauma doesn't increase the CDI incidence [46, 47].
2. Metronidazole was not associated with a high CDI risk [48].

Prevention, diagnosis and treatment methods

The prevention methods involve hand hygiene and reduction of environmental contamination [33, 49, 50]. Most sources attest that Chlorhexidine has no effect on the incidence of CDI [51], [52], while another source states that it is unclear [39] and only one source has reported a decreasing incidence, with 7% [53]. The probiotics usage is not a widely used preventive measure [33].

The diagnostic methods include the cell cytotoxicity test (CCT), which is the measurement of toxins in the feces or the cytotoxigenic culture (CC) study [54]. RT-PCR is a useful method in order to identify the CD toxins in the stool, though a very expensive one compared to other methods [5]. Nucleic acid amplification test is used in order to identify the CD strains [33, 54] with Glutamate dehydrogenase tests [54].

A strategy for identifying patients with a high risk for CDI is proven to be efficient for reducing the mortality rate in the ICU [55]. Therefore, the physiologic scores used for the assessment of the patients in the ICU may be quite useful – Acute physiology and chronic health evaluation II (APACHE II) [56-60], APACHE III [61], APACHE IV [34], Zar's score [23, 62, 63] and Charlson comorbidity index (CCI) [38, 64-66].

The treatment methods include basic antimicrobial programs and antimicrobial management, the usage of antibiotics (e.g. vancomycin) [67]. The first-line treatment is represented by metronidazole administration, while the second-line treatment is represented by administration of vancomycin or fidaxomicin [3, 33]. Mild or moderate CDI should be treated with oral vancomycin [3] or metronidazole [3, 40, 48, 68], other studies reported no effectiveness for metronidazole [33]. Severe cases were treated with intravenous/ileostoma-administered vancomycin [68]. Vancomycin is administered in 48.3% of cases, whereas metronidazole is administered in 34.5% of cases according to one study [69]. Other sources report that vancomycin usage should be revised [67]. Recent new treatment options involve fecal microbiota transplant [3] which was reported as an effective treatment option [70, 71]. Bezlotoxumab – antibody specific for *Clostridium difficile* is proven to be effective in the treatment of this infection [33].

Conclusions

1. *Clostridium difficile* remains an actual controversial issue according to the articles reviewed within this study. The present study concluded that the most reported risk factors were the following:

- Antibiotic usage (12 sources);
- Proton pump inhibitors (9 sources);
- Long duration of hospitalization (5 sources);
- Advanced age (4 sources).

2. No adequate or sufficiently proven preventive measures were found, the only exception accounts for the reduction of in-hospital circulation of different doctors and visitors.

3. The following useful tools, for the diagnostic act, were identified – APACHE scales, CCI and the Zar's score. The most efficient, though the most expensive, clinical test is RT-PCR.

4. The most efficient and wide-spread treatment options were as follows:

- Oral vancomycin and metronidazole given in mild cases, as well as administered through the intravenous/ileostoma route in severe cases;
- Fecal microbiota transplant.

References

1. Halaweish I, Alam HB. Surgical management of severe colitis in the Intensive Care Unit. *J Intensive Care Med.* 2015;30(8):451-461. doi: 10.1177/0885066614534941.
2. Rupnik M, Janezic S. An update on *Clostridium difficile* toxinotyping. 2016;54(1):13-18. doi: 10.1128/JCM.02083-15
3. Han S, Shannahan S, Pellish R. Fecal microbiota transplant: treatment options for *clostridium difficile* infection in the intensive care unit. *J Intensive Care Med.* 2016;31(9):577-586. doi: 10.1177/0885066615594344.
4. Kiu R, Caim S, Alcon-Giner C, et al. Preterm infant-associated *clostridium tertium*, *clostridium cadaveris*, and *clostridium paraputrificum* strains: genomic and evolutionary insights. *Genome Biol Evol.* 2017;9(10):2707-2714. doi:10.1093/gbe/evx210.
5. Yoldaş Ö, Altınış M, Cufalı D, Aşık G, Keşli R. A diagnostic algorithm for the detection of *clostridium difficile*-associated diarrhea. *Balkan Med J.* 2016;33(1):80-86. doi: 10.5152/balkanmedj.2015.15159.
6. Mi H, Bao R, Xiao Y, et al. Colonization of toxigenic *Clostridium difficile* among intensive care unit patients: a multi-centre cross-sectional study. *Front Cell Infect Microbiol.* 2020;10:1-8. doi:10.3389/fcimb.2020.00012
7. European Centre for Disease Prevention and Control (ECDC). Healthcare-associated infections acquired in intensive care units [Internet]. Stockholm: ECDC; 2018- [cited 2020 June 12]. Available from: <https://www.ecdc.europa.eu/en/healthcare-associated-infections-acquired-intensive-care-units>
8. Ofori E, Ramai D, Dhawan M, Mustafa F, Gasperino J, Reddy M. Community-acquired *Clostridium difficile*: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. *J Hosp Infect.* 2018;99(4):436-442. doi: 10.1016/j.jhin.2018.01.015.
9. Faden HS, Dryja D. Importance of asymptomatic shedding of *Clostridium difficile* in environmental contamination of a neonatal intensive care unit. *Am J Infect Control.* 2015;43(8):887-888. doi: 10.1016/j.ajic.2015.04.187.
10. Sandora TJ, Bryant KK, Cantey JB, Elward AM, Yokoe DS, Bartlett AH. SHEA neonatal intensive care unit (NICU) white paper series: practical approaches to *Clostridioides difficile* prevention. *Infect Control Hosp Epidemiol.* 2018;39(10):1149-1153. doi: 10.1017/ice.2018.209.
11. Bouza E, Rodríguez-Créixems M, Alcalá L, et al. Is *Clostridium difficile* infection an increasingly common severe disease in adult intensive care units? A 10-year experience. *J Crit Care.* 2015;30(3):543-549. doi:10.1016/j.jcrc.2015.02.011.
12. Salva S, Duran N, Rodríguez V, et al. *Clostridium difficile* in the ICU: study of the incidence, recurrence, clinical characteristics and complications in a University Hospital. *Med Intensiva.* 2014;38(3):140-145. doi:10.1016/j.medin.2013.03.012.
13. Magee G, Strauss ME, Thomas SM, Brown H, Baumer D, Broderick KC. Impact of *Clostridium difficile*-associated diarrhea on acute care length of stay, hospital costs, and readmission: a multicenter retrospective study of in-patients, 2009-2011. *Am J Infect Control.* 2015;43(11):1148-1153. doi: 10.1016/j.ajic.2015.06.004.
14. Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton pump inhibitors do not increase risk for *Clostridium difficile* infection in the Intensive Care Unit. *Am J Gastroenterol.* 2016;111(11):1641-1648. doi: 10.1038/ajg.2016.343.
15. Tschudin-Sutter S, Carroll KC, Tamma PD, et al. Impact of toxigenic *clostridium difficile* colonization on the risk of subsequent *C. difficile* infection in intensive care unit patients. *Infect Control Hosp Epidemiol.* 2015;36(11):1324-1329. doi: 10.1017/ice.2015.177.
16. Zarandi ER, Mansouri S, Nakhaee N, Sarafzadeh F, Iranmanesh Z, Moradi M. Frequency of antibiotic associated diarrhea caused by *Clostridium difficile* among hospitalized patients in intensive care unit, Kerman, Iran. *Gastroenterol Hepatol Bed Bench.* 2017;10(3):229-234.
17. Segar L, Easow JM, Srirangaraj S, Hanifah M, Joseph NM. Prevalence of *Clostridium difficile* infection among the patients attending a tertiary care teaching hospital. *Indian J Pathol Microbiol.* 2017;60(2):221-225. doi: 10.4103/0377-4929.208383.
18. Dionne JC, Sullivan K, Mbuagbaw L, et al. Diarrhoea: interventions, consequences and epidemiology in the intensive care unit (DICE-ICU): a protocol for a prospective multicentre cohort study. *BMJ Open.* 2019;9(6):e028237. doi: 10.1136/bmjopen-2018-028237.
19. Thongkoom P, Kanchanahareutai S, Chantrakooptungkul S, Rahule S. Characteristics and demographic distributions of toxigenic *Clostridium difficile* strains in Rajavithi Hospital, 2009-2015. *J Med Assoc Thai.* 2016;99 Suppl 2:S195-S200.
20. Abulhasan YB, Abdullah AA, Shetty SA, Ramadan MA, Yousef W. Healthcare-associated infections in a neurocritical care unit of a developing country. *Neurocrit Care.* 2020;32(3):836-846. doi: 10.1007/s12028-019-00856-8.
21. Lee JC, Hung YP, Lin HJ, Tsai PJ, Ko WC. *Clostridium difficile* infections in medical intensive care units of a medical center in Southern Taiwan: variable seasonality and disease severity. *PLoS One.* 2016;11(8):e0160760. doi: 10.1371/journal.pone.0160760.
22. Alberda C, Marcushamer S, Hewer T, Journault N, Kutsogiannis D. Feasibility of a lactobacillus casei drink in the intensive care unit for prevention of antibiotic-associated diarrhea and *clostridium difficile*. *Nutrients.* 2018;10(5):539. doi: 10.3390/nu10050539.
23. Riley TV, Kimura T. The epidemiology of *Clostridium difficile* infection in Japan: a systematic review. *Infect Dis Ther.* 2018;7(1):39-70. doi: 10.1007/s40121-018-0186-1.
24. Silva CD, Silva Júnior M. Strategies for appropriate antibiotic use in intensive care unit. *Einstein (Sao Paulo).* 2015;13(3):448-453. doi: 10.1590/S1679-45082015RW3145.
25. Spigaglia P, Mastrantonio P, Barbanti F. Antibiotic resistances of *Clostridium difficile*. *Adv Exp Med Biol.* 2018;1050:137-159. doi: 10.1007/978-3-319-72799-8_9.
26. Jasiak NM, Alaniz C, Rao K, Veltman K, Nagel JL. Recurrent *Clostridium difficile* infection in intensive care unit patients. *Am J Infect Control.* 2016;44(1):36-40. doi: 10.1016/j.ajic.2015.08.013.
27. Squellati R. Evidence-based practice in the treatment for antibiotic-associated diarrhea in the Intensive Care Unit. *Crit Care Nurs Clin North Am.* 2018;30(1):87-99. doi: 10.1016/j.cnc.2017.10.008.
28. Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: risks and benefits of stress ulcer prophylaxis. *World J Crit Care Med.* 2016;5(1):57-64. doi: 10.5492/wjccm.v5.i1.57.

29. Huang HB, Jiang W, Wang CY, Qin HY, Du B. Stress ulcer prophylaxis in intensive care unit patients receiving enteral nutrition: a systematic review and meta-analysis. *Crit Care*. 2018;22(1):1-9. doi: 10.1186/s13054-017-1937-1.
30. Alhazzani W, Alshamsi F, Belley-Cote E, et al. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. *Intensive Care Med*. 2018;44(1):1-11. doi: 10.1007/s00134-017-5005-8.
31. Reynolds PM, MacLaren R. Re-evaluating the utility of stress ulcer prophylaxis in the critically ill patient: a clinical scenario-based meta-analysis. *Pharmacotherapy*. 2019;39(3):408-420. doi: 10.1002/phar.2172.
32. Krag M, Perner A, Wetterslev J, et al. Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. *Acta Anaesthesiol Scand*. 2015;59(5):576-585. doi: 10.1111/aas.12508.
33. Leedahl DD, Personett HA, Nagpal A, Barreto EF. Prevention of *Clostridium difficile* infection in critically ill adults. *Pharmacotherapy*. 2019;39(3):399-407. doi: 10.1002/phar.2200.
34. Van Beurden YH, Dekkers OM, Bomers MK, et al. An outbreak of *clostridium difficile* ribotype 027 associated with length of stay in the intensive care unit and use of selective decontamination of the digestive tract: a case control study. *PLoS One*. 2016;11(8):1-13. doi: 10.1371/journal.pone.0160778.
35. Daneman N, Rishu AH, Pinto R, et al. 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: A pilot randomized clinical trial. *Trials*. 2018;19(1):1-9. doi: 10.1186/s13063-018-2474-1.
36. Smith EZ, Northup PG, Argo CK. Predictors of mortality in cirrhosis in-patients with *clostridium difficile* infection. *J Clin Gastroenterol*. 2018;52(8):747-751. doi: 10.1097/MCG.0000000000000868.
37. Wischmeyer PE, McDonald D, Knight R. Role of the microbiome, probiotics, and "dysbiosis therapy" in critical illness. *Curr Opin Crit Care*. 2016;22(4):347-353. doi: 10.1097/MCC.0000000000000321.
38. Skoutelis A, Pefanis A, Tsiodras S, et al. Point-prevalence survey of healthcare facility-onset healthcare-associated *Clostridium difficile* infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. *PLoS One*. 2017;12(8):e0182799. doi: 10.1371/journal.pone.0182799.
39. Bui LN, Swan JT, Shirkey BA, Olsen RJ, Long SW, Graviss EA. Chlorhexidine bathing and *Clostridium difficile* infection in a surgical intensive care unit. *J Surg Res*. 2018;228:107-111. doi: 10.1016/j.jss.2018.02.063.
40. Cui Y, Dong D, Zhang L, et al. Risk factors for *Clostridioides difficile* infection and colonization among patients admitted to an intensive care unit in Shanghai, China. *BMC Infect Dis*. 2019;19(1):1-9. doi: 10.1186/s12879-019-4603-1.
41. Watkins RR, Mangira C, Muakkassa F, Donskey CJ, Haller NA. *Clostridium difficile* Infection in trauma, surgery, and medical patients admitted to the Intensive Care Unit. *Surg Infect (Larchmt)*. 2018;19(5):488-493. doi: 10.1089/sur.2017.253.
42. Hines AG, Freifeld A, Zhao X, et al. *Clostridium difficile* stool shedding in infants hospitalized in two neonatal intensive care units is lower than previous point prevalence estimates using molecular diagnostic methods. *BMC Pediatr*. 2018;18(1):1-7. doi: 10.1186/s12887-018-1113-z.
43. Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of *clostridium difficile* infection in the molecular test era. *JAMA Intern Med*. 2015;175(11):1792-1801. doi: 10.1001/jamainternmed.2015.4114.
44. Sartelli M, Di Bella S, McFarland LV, et al. 2019 update of the WSES guidelines for management of Clostridioides (*Clostridium difficile*) infection in surgical patients 11 Medical and Health Sciences 1103 Clinical Sciences. *World J Emerg Surg*. 2019;14(1):1-29. doi: 10.1186/s13017-019-0228-3.
45. Silveti S, Landoni G. Is *clostridium difficile* the new bugaboo after cardiac surgery? *J Thorac Dis*. 2018;10(Suppl 26):S3278-S3280. doi: 10.21037/jtd.2018.08.99.
46. Gabriel V, Grigorian A, Phillips JL, et al. A propensity score analysis of *clostridium difficile* infection among adult trauma patients. *Surg Infect (Larchmt)*. 2018;19(7):661-666. doi: 10.1089/sur.2018.110.
47. Karamanos E, Gupta AH, Stanton CN, Mohamed A, Patton JH, Schmoekel N. *Clostridium difficile*-associated infection in trauma patients: development of the *Clostridium difficile* influencing factors (CDIF) score. *Perm J*. 2018;22:1-5. doi: 10.7812/TPP/18-013.
48. Sabbah MA, Schorr C, Czosnowski QA, et al. Risk of *Clostridium difficile* infection in intensive care unit patients with sepsis exposed to metronidazole. *Infect Dis (Lond)*. 2015;47(4):197-202. doi: 10.3109/00365548.2014.978890.
49. Jullian-Desayes I, Landelle C, Mallaret MR, Brun-Buisson C, Barbut F. *Clostridium difficile* contamination of health care workers' hands and its potential contribution to the spread of infection: Review of the literature. *Am J Infect Control*. 2017;45(1):51-58. doi: 10.1016/j.ajic.2016.08.017.
50. Krein SL, Mayer J, Harrod M, et al. Identification and characterization of failures in infectious agent transmission precaution practices in hospitals: a qualitative study. *JAMA Intern Med*. 2018;178(8):1016-1022. doi: 10.1001/jamainternmed.2018.1898.
51. Kengen R, Thoonen E, Daveson K, Loong B, Rodgers H, Beckingham W, Kennedy K, Suwandarathne R. Chlorhexidine washing in intensive care does not reduce bloodstream infections, blood culture contamination and drug-resistant microorganism acquisition: an interrupted time series analysis. *Crit Care Resusc*. 2018;20(3):231-240.
52. Noto MJ, Domenico HJ, Byrne DW, et al. Chlorhexidine bathing and healthcare-associated infections: a randomized clinical trial. *JAMA*. 2015;313(4):369-378. doi: 10.1001/jama.2014.18400.
53. Frost SA, Alogso MC, Metcalfe L, et al. Chlorhexidine bathing and healthcare-associated infections among adult intensive care patients: A systematic review and meta-analysis. *Crit Care*. 2016;20(1):16-21. doi: 10.1186/s13054-016-1553-5.
54. Planche T, Wilcox MH. Diagnostic pitfalls in *Clostridium difficile* infection. *Infect Dis Clin North Am*. 2015;29(1):63-82. doi: 10.1016/j.idc.2014.11.008.
55. Cruz-Betancourt A, Cooper CD, Sposato K, et al. Effects of a predictive preventive model for prevention of *Clostridium difficile* infection in patients in intensive care units. *Am J Infect Control*. 2016;44(4):421-424. doi: 10.1016/j.ajic.2015.11.010.
56. Malamood M, Nellis E, Ehrlich AC, Friedenber FK. Vancomycin enemas as adjunctive therapy for *Clostridium difficile* infection. *J Clin Med Res*. 2015;7(6):422-427. doi: 10.14740/jocmr.2117w.
57. Flatow VH, Ibragimova N, Divino CM, et al. Quality outcomes in the surgical intensive care unit after electronic health record implementation. *Appl Clin Inform*. 2015;6(4):611-618. doi: 10.4338/ACI-2015-04-RA-0044.
58. Li Y, Huang Y, Li Y, Nie Y. Clinical characteristics of *Clostridium difficile*-associated diarrhea among patients in a tertiary care center in China. *Pakistan J Med Sci*. 2016;32(3):736-741. doi: 10.12669/pjms.323.9400.
59. Chauv S, Fontaine GV, Hoang QP, et al. Risk of resistant organisms and *Clostridium difficile* with prolonged systemic antibiotic prophylaxis for central nervous system devices. *Neurocrit Care*. 2016;25(1):128-132. doi: 10.1007/s12028-016-0254-x.
60. Karanika S, Paudel S, Zervou FN, Grigoras C, Zacharioudakis IM, Mylonakis E. Prevalence and clinical outcomes of *Clostridium difficile* infection in the intensive care unit: a systematic review and meta-analysis. *Open Forum Infect Dis*. 2016;3(1):ofv186. doi: 10.1093/ofid/ofv186.
61. Len EK, Akkisetty R, Royal S, et al. Increased healthcare-associated infections in a surgical intensive care unit related to boarding non-surgical patients. *Surg Infect (Larchmt)*. 2019;20(4):332-337. doi: 10.1089/sur.2018.240.
62. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for *Clostridium difficile*-associated diarrhoea in adults. *Cochrane Database Syst Rev*. 2017;3(3):CD004610. doi: 10.1002/14651858.CD004610.pub5.
63. Barbut F, Galperine T, Vanhems P, et al. Quality of life and utility decrement associated with *Clostridium difficile* infection in a French hospital setting. *Health Qual Life Outcomes*. 2019;17(1):1-7. doi: 10.1186/s12955-019-1081-5.
64. Bhandari S, Pandey RK, Dahal S, Shahreyar M, Dhakal B, Jha P, Venkatesan T. Risk, outcomes, and predictors of *Clostridium difficile* infection

- in lymphoma: a nationwide study. *South Med J*. 2018;111(10):628-633. doi: 10.14423/SMJ.0000000000000872.
65. Seo MR, Kim J, Lee Y, Lim DG, Pai H. Prevalence, genetic relatedness and antibiotic resistance of hospital-acquired *clostridium difficile* PCR ribotype 018 strains. *Int J Antimicrob Agents*. 2018;51(5):762-767. doi: 10.1016/j.ijantimicag.2018.01.025.
66. Archbald-Pannone LR, McMurry TL, Guerrant RL, Warren CA. Delirium and other clinical factors with *Clostridium difficile* infection that predict mortality in hospitalized patients. *Am J Infect Control*. 2015;43(7):690-693. doi: 10.1016/j.ajic.2015.03.017.
67. Doernberg SB, Chambers HF. Antimicrobial stewardship approaches in the Intensive Care Unit. *Infect Dis Clin North Am*. 2017;31(3):513-534. doi: 10.1016/j.idc.2017.05.002.
68. Prechter F, Katzer K, Bauer M, Stallmach A. Sleeping with the enemy: *Clostridium difficile* infection in the intensive care unit. *Crit Care*. 2017;21(1):1-10. doi: 10.1186/s13054-017-1819-6.
69. Bruensing J, Buendgens L, Jochum C, et al. Diagnostik und Therapie von *Clostridium-difficile*-Infektionen auf deutschen Intensivstationen – eine Umfrage unter Intensivmedizinern [Management of *Clostridium difficile* infections at German intensive care units – results from a survey among intensivists]. *Z Gastroenterol*. 2018;56(06):551-560. doi: 10.1055/s-0044-102103. German.
70. Akrami K, Sweeney DA. The microbiome of the critically ill patient. *Curr Opin Crit Care*. 2018;24(1):49-54. doi: 10.1097/MCC.0000000000000469.
71. Limketkai BN, Hender S, Ting PS, Parian AM. Fecal microbiota transplantation for the critically ill patient. *Nutr Clin Pract*. 2019;34(1):73-79. doi: 10.1002/ncp.10228.

Authors' ORCID iDs and academic degrees

Gheorghe Placinta, MD, PhD, Professor – <https://orcid.org/0000-0001-5964-1572>.
Valentina Vorobjit, MD, PhD, Associate Professor – <https://orcid.org/0000-0001-5581-371X>.
Victor Pantea, MD, PhD, Professor – <https://orcid.org/0000-0003-3996-3317>.
Lilia Cojuhari, MD, PhD, Associate Professor – <https://orcid.org/0000-0001-5211-6476>.
Valentin Ceboatarescu, MD, PhD, Associate Professor – <https://orcid.org/0000-0003-1089-0038>.
Lidia Placinta, MD, Assistant Professor – <https://orcid.org/0000-0001-9969-867X>.
Dan Croitoru, MD, Undergraduate – <https://orcid.org/0000-0002-8915-0157>.

Authors' contribution

GP conceptualized the project and designed the research; VV revised the manuscript and designed the research; VP revised the manuscript critically; LC interpreted the data; VC performed the laboratory work; LP drafted the manuscript; DC drafted the manuscript and designed the research. All the authors revised and approved the final version of the manuscript.

Funding

This study was supported by the Research Ethics Committee of *Nicolae Testemitanu* State University of Medicine and Pharmacy. The trial was the authors' initiative. The authors are independent and take responsibility for the integrity of the data and accuracy of the data analysis.

Ethics approval and consent to participate

No approval was required for this study.

Conflict of Interests

No competing interests were disclosed.